The use of procalcitonin as a biomarker for the diagnosis of systemic infections and sepsis has significantly increased in the past few years. Overuse of antibiotics has increased the risk of antibiotic resistance. The Centers for Disease Control and Prevention (CDC) has estimated that about 2 million people get antibiotic-resistant infections in the U.S., out of which at least 23,000 people die every year. This has put a burden in terms of treatment cost and necessity of better diagnostic tools such as biomarkers. Procalcitonin (PCT), one of the blood biomarkers, is used at the different clinical stages and infections such as early detection of sepsis and therapy monitoring for respiratory infections. Identification of the bacterial origin of infection is the utmost important aspect of therapy.
PCT can efficiently diagnose bacterial infection, especially in the case of hospital emergency and intensive care units. In addition, PCT-guided care is cost-effective, and it requires less hospital stay. For instance, on average it costs around USD 2,759 per PCT-treated patient. An economic study of PCT-guided antibiotic treatment of Acute Respiratory Infections has revealed that net savings can range from USD 73,326 in the ICU to more than USD 5 million in the outpatient clinic and ED setting; total savings could be more than USD 6 million.
Global procalcitonin market was valued at USD 118.7 million in 2018, growing at a CAGR of 14.9% during the forecast period of 2019–2026.
To learn more about key trends >> Download Sample Report
For a better understanding of the global procalcitonin market, we have segmented the market by application.
By application, the market is segmented into medical and research. Medical application was valued at USD 7.74 million in 2018. The prevalence of sepsis has significantly increased in the last decade due to the aging population, increasing drug-resistance, and the rising number of more virulent pathogens. Additionally, malnutrition, poor sanitation, and lack of access to vaccines and timely treatments in the developing region have increased the overall incidence rate. It helps early diagnosis. It also helps in reducing the overuse of antibiotics in case of bronchitis and acquired pneumonia. For example, viruses cause acute bronchitis. However, 80% of patients are prescribed antibiotics and around 50% of antimicrobial use in the inpatient setting are not required. Hence, procalcitonin comes handy in determining the cause of infection without worsening the clinical outcomes.
Global procalcitonin market by Americas, Asia Pacific, Europe, and the Middle East and Africa.
To understand geography trends >> Download Sample Report
North America is dominating the market in the forecast period. Sepsis is a topmost condition to account for inpatient hospital expense in the U.S. Centers for Disease Control and Prevention (CDC) has estimated that each year around 1.7 million adults in America suffer from sepsis; nearly 270,000 Americans die, and 1 in 3 patients who die in a hospital have sepsis. It is a national epidemic and one of the largest unmet medical conditions responsible for almost half of the hospital deaths. It is also among the top five causes of hospitalization in adults. In the last decade, the treatment cost of sepsis has tripled to USD 27 billion. These factors have driven the overall demand for a comprehensive plan to treat sepsis and reduce the treatment cost. Moreover, Prevalence of the sepsis in the region is increasing rapidly. As per Canadian Sepsis Foundation, sepsis has been reported in 15% of all Intensive Care Unit (ICU) patients, and it is among 12 leading causes of death in Canada. Use of procalcitonin testing is an effective way of saving money by reducing the use of an unnecessary antibiotic. As per modeling study published in March 2015 by Clinical Chemistry and Laboratory Medicine, procalcitonin-guided care could save USD 700,000 as compared to usual care in 2014 in the U.S.
Europe is the second leading region in procalcitonin market. As per the U.K Sepsis Trust, sepsis kills 52,000 people and affects 25,000 children every year, 5 people die due to sepsis every hour in the U.K. In Germany, it is the third most common cause of death and claims 60,000 lives in a year. In addition, if the overall number of admissions for sepsis were reduced by 10%, 20%, or 30% then the annual cost savings can be 83 million euros, 166 million euros, or 249 million euros respectively. Adoption of guided antibiotic programs and procalcitonin test would help in providing better treatment of these indications.
Middle East and Africa are offering lucrative opportunities for the market. Sepsis is the major contributor to the global burden of diseases where low and middle-income countries witness a major number of cases and deaths from sepsis. This can be attributed to mortality, low awareness, poverty, and under-resourced public health care delivery systems. The International Journal of Infectious Diseases conducted a study in 2017 to examine the incidences of late-onset sepsis (LOS) in neonatal intensive care units (NICUs) in Arab states. The study was conducted for 2 years in five NICUs in Kuwait, Saudi Arabia, and the United Arab Emirates. LOS poses a major burden in these areas due to increasing care of premature babies. Procalcitonin tests will help in reducing mortality in these areas, hence, adoption will increase in future.
Some of the prominent players in the market are Thermo Fisher Scientific, Diazyme, Roche Diagnostics, EKF Diagnostics Holdings plc, Siemens Healthcare Diagnostics Inc, Diasorin Inc, Biomerieux, Inc, Fujirebio Diagnostics, Inc and Abbott.